RU2006119294A - Фармацевтические составы с улучшенными фармацевтическими свойствами, содержащие вкусовые вещества - Google Patents

Фармацевтические составы с улучшенными фармацевтическими свойствами, содержащие вкусовые вещества Download PDF

Info

Publication number
RU2006119294A
RU2006119294A RU2006119294/15A RU2006119294A RU2006119294A RU 2006119294 A RU2006119294 A RU 2006119294A RU 2006119294/15 A RU2006119294/15 A RU 2006119294/15A RU 2006119294 A RU2006119294 A RU 2006119294A RU 2006119294 A RU2006119294 A RU 2006119294A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
pharmaceutical
salt
pradofloxacin
enrofloxacin
Prior art date
Application number
RU2006119294/15A
Other languages
English (en)
Other versions
RU2377018C2 (ru
Inventor
Патрик БОШЕ (DE)
Патрик Боше
Сабине БОНГЕРТС (DE)
Сабине БОНГЕРТС
Венката-Рангарао КАНИКАНТИ (DE)
Венката-Рангарао КАНИКАНТИ
Original Assignee
Байер ХельсКер АГ (DE)
Байер ХельсКер АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер ХельсКер АГ (DE), Байер ХельсКер АГ filed Critical Байер ХельсКер АГ (DE)
Publication of RU2006119294A publication Critical patent/RU2006119294A/ru
Application granted granted Critical
Publication of RU2377018C2 publication Critical patent/RU2377018C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (4)

1. Твердый фармацевтический состав, содержащий фармацевтическое действующее вещество, ароматическое вещество и по меньшей мере 1,5 мас.% высокодисперсного диоксида кремния в пересчете на общую массу готового фармацевтического состава.
2. Твердый фармацевтический состав по п.1, содержащий в качестве фармацевтического действующего вещества энрофлоксацин, соль энрофлоксацина или гидрат энрофлоксацина или его соль.
3. Твердый фармацевтический состав по п.1, содержащий в качестве фармацевтического действующего вещества прадофлоксацин, соль прадофлоксацина или гидрат прадофлоксацина или его соль.
4. Способ получения твердого фармацевтического состава по п.1, состоящий в том, что вкусовое вещество гранулируют с высокодисперсным оксидом кремния, а также одним или несколькими действующими веществами и обычными фармацевтическими добавками и/или вспомогательными веществами.
RU2006119294/15A 2003-11-04 2004-10-30 Фармацевтические составы с улучшенными фармацевтическими свойствами, содержащие вкусовые вещества RU2377018C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10351448A DE10351448A1 (de) 2003-11-04 2003-11-04 Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE10351448.1 2003-11-04

Publications (2)

Publication Number Publication Date
RU2006119294A true RU2006119294A (ru) 2007-12-27
RU2377018C2 RU2377018C2 (ru) 2009-12-27

Family

ID=34559323

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006119294/15A RU2377018C2 (ru) 2003-11-04 2004-10-30 Фармацевтические составы с улучшенными фармацевтическими свойствами, содержащие вкусовые вещества

Country Status (31)

Country Link
US (2) US7858120B2 (ru)
EP (2) EP1682144B1 (ru)
JP (1) JP4892351B2 (ru)
KR (2) KR20120093299A (ru)
CN (2) CN1972687B (ru)
AR (2) AR046226A1 (ru)
AT (1) ATE454891T1 (ru)
AU (1) AU2004286785B2 (ru)
BR (1) BRPI0416188A (ru)
CA (1) CA2544344C (ru)
CR (1) CR8371A (ru)
CY (2) CY1110541T1 (ru)
DE (2) DE10351448A1 (ru)
DK (1) DK1682144T3 (ru)
ES (1) ES2337793T3 (ru)
HK (1) HK1107008A1 (ru)
HR (1) HRP20100189T1 (ru)
IL (1) IL175147A (ru)
LU (1) LU91882I2 (ru)
MY (1) MY149864A (ru)
NO (1) NO339326B1 (ru)
NZ (1) NZ546921A (ru)
PE (1) PE20050575A1 (ru)
PL (1) PL1682144T3 (ru)
PT (1) PT1682144E (ru)
RU (1) RU2377018C2 (ru)
SI (1) SI1682144T1 (ru)
TW (1) TWI343819B (ru)
UA (1) UA85691C2 (ru)
WO (1) WO2005044271A1 (ru)
ZA (1) ZA200603451B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN100360131C (zh) * 2006-01-24 2008-01-09 新昌国邦化学工业有限公司 一种掩味恩诺沙星的生产方法
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
DE102007004732A1 (de) * 2007-01-31 2008-08-07 Bayer Healthcare Ag Enrofloxacin-Hexahydrat
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US20110223297A1 (en) * 2010-03-12 2011-09-15 Pepsico., Inc. Anti-Caking Agent for Flavored Products
KR102253847B1 (ko) 2012-12-19 2021-05-21 바이엘 애니멀 헬스 게엠베하 향상된 수용성 및 우수한 저장 안정성을 가지는 정제
WO2015042596A1 (en) * 2013-09-23 2015-03-26 Kindred Biosciences, Inc Treatment of atopic dermatitis in non-human animals
TWI749007B (zh) * 2016-04-27 2021-12-11 日商富山化學工業股份有限公司 包含甲苯磺酸托氟沙星之錠劑
TWI727036B (zh) * 2016-04-27 2021-05-11 日商富山化學工業股份有限公司 包含甲苯磺酸托氟沙星、崩解劑及酸性胺基酸之錠劑
CN105997908B (zh) * 2016-06-03 2019-06-21 湖北回盛生物科技有限公司 一种马波沙星牛肉风味片及其制备方法
EP3784656B1 (de) 2018-04-25 2023-06-28 Elanco Animal Health GmbH Verfahren zur hydrolyse von chinoloncarbonsäureestern

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA413698A (en) * 1943-07-06 Frederick Dauster John Breathing valve
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (ru) 1985-09-18 1990-05-05 Pfizer
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
US4910023A (en) 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
US5256699A (en) * 1988-10-18 1993-10-26 Ciba-Geify Corporation Dispersible tablet formulation of diclofenac acid free base
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
NZ267002A (en) * 1993-06-04 1997-07-27 Warner Lambert Co Chewable cold/sinus relief preparation comprising antihistamine and decongestant in a carrier consisting of silicon dioxide
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
PT725037E (pt) * 1995-02-04 2001-07-31 Degussa Granulados a base de dioxido de silicio preparado pirogenicamente processo para a sua preparacao e sua utilizacao
US6323213B1 (en) 1996-02-23 2001-11-27 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
US20010018417A1 (en) * 1996-07-01 2001-08-30 Carson James W. Virginiamycin mixture
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6607754B1 (en) * 1997-07-11 2003-08-19 Upsher-Smith Laboratories, Inc. Delivery of Hypericum perforatum (St. John's Wort) in tablet form
AU741992B2 (en) * 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
HU227070B1 (en) * 1999-08-11 2010-06-28 Egis Gyogyszergyar Nyilvanosan Immediate release pharmaceutical composition containing ciprofloxacin and process for its production
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
EP1263409A1 (en) 2000-03-03 2002-12-11 Ranbaxy Laboratories, Limited Orally administered controlled delivery system for once daily administration of ciprofloxacin
DE10031044A1 (de) * 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
EP1247456A3 (en) * 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20030235618A1 (en) * 2001-10-22 2003-12-25 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
US20030170310A1 (en) * 2002-03-08 2003-09-11 Hardeep Wadhwa Tasteless, directly compressible, fast-dissolving complexes and pharmaceutical formulations thereof
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
HUE046606T2 (hu) * 2009-11-09 2020-03-30 Wyeth Llc Neratinib maleát tabletta formái

Also Published As

Publication number Publication date
DE502004010644D1 (de) 2010-03-04
IL175147A (en) 2014-04-30
AR046226A1 (es) 2005-11-30
KR101325146B1 (ko) 2013-11-07
TWI343819B (en) 2011-06-21
NO339326B1 (no) 2016-11-28
AU2004286785B2 (en) 2010-08-12
US20070196466A1 (en) 2007-08-23
PT1682144E (pt) 2010-03-09
CY2011017I1 (el) 2016-12-14
ZA200603451B (en) 2007-07-25
CR8371A (es) 2006-10-10
CN1972687A (zh) 2007-05-30
RU2377018C2 (ru) 2009-12-27
BRPI0416188A (pt) 2007-01-23
KR20120093299A (ko) 2012-08-22
UA85691C2 (ru) 2009-02-25
HRP20100189T1 (hr) 2010-05-31
NO20062605L (no) 2006-07-25
CN102335117A (zh) 2012-02-01
EP1682144B1 (de) 2010-01-13
CA2544344A1 (en) 2005-05-19
US20110065719A1 (en) 2011-03-17
CY1110541T1 (el) 2015-04-29
PL1682144T3 (pl) 2010-06-30
EP1682144A1 (de) 2006-07-26
HK1107008A1 (en) 2008-03-28
MY149864A (en) 2013-10-31
CY2011017I2 (el) 2016-12-14
DK1682144T3 (da) 2010-05-17
AU2004286785A1 (en) 2005-05-19
US7858120B2 (en) 2010-12-28
AR108594A2 (es) 2018-09-05
AU2004286785A8 (en) 2009-08-13
TW200517144A (en) 2005-06-01
ES2337793T3 (es) 2010-04-29
CN1972687B (zh) 2013-01-23
KR20060109910A (ko) 2006-10-23
PE20050575A1 (es) 2005-10-27
ATE454891T1 (de) 2010-01-15
LU91882I2 (fr) 2013-04-12
JP2007510001A (ja) 2007-04-19
DE10351448A1 (de) 2005-06-09
EP2080515A1 (de) 2009-07-22
WO2005044271A1 (de) 2005-05-19
CA2544344C (en) 2013-10-15
NZ546921A (en) 2009-08-28
JP4892351B2 (ja) 2012-03-07
SI1682144T1 (sl) 2010-05-31
IL175147A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
RU2006119294A (ru) Фармацевтические составы с улучшенными фармацевтическими свойствами, содержащие вкусовые вещества
EA200400471A1 (ru) Оральная дозированная форма пропиверина
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
WO2004033418A3 (en) Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
CA2452577A1 (en) Soft capsules
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
WO2007070504A3 (en) Stable and palatable oral liquid sumatriptan compositions
WO2002085301A3 (en) Indole, azaindole and related heterocyclic amidopiperazine derivatives
CA2429844A1 (en) Mch antagonists and their use in the treatment of obesity
WO2005016261A3 (en) Aripiprazole and haloperidol pamoate salts
NO20034126L (no) Stabilisering av bestanddeler som gir aroma
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
WO2001041748A3 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
WO2004037193A3 (en) Chromones and chromone derivatives and uses thereof
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
CA2525874A1 (en) Pharmaceutical compositions of varenicline
WO2007108010B1 (en) Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
WO2002070464A3 (en) Hydrazones and their therapeutic use
JP2005281306A (ja) 歯磨き組成物
WO2004096116A3 (en) Diazabicyclononene derivatives
WO2005030209A8 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
JP2004043475A (ja) 経口用セファロスポリン製剤
WO2004037228A8 (en) Sustained release compositions containing alfuzosin
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives

Legal Events

Date Code Title Description
TZ4A Amendments of patent specification
PC41 Official registration of the transfer of exclusive right

Effective date: 20130207